Decoy Therapeutics Inc. (DCOY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2M 4M 6M Q2 '18: 1.1M Q3 '18: 1.2M Q4 '18: 1.1M Q1 '19: 1.5M Q2 '19: 2.2M Q3 '19: 2.6M Q4 '19: 3.5M Q1 '20: 3.9M Q2 '20: 4.3M Q3 '20: 4.8M Q4 '20: 5.2M Q1 '21: 5.4M Q2 '21: 4.7M Q3 '21: 3.3M Q4 '21: 1.8M Q1 '22: 571.4K Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23

Gross Profit TTM

0 700K 1.4M 2.1M Q4 '17: 768K Q1 '18: 699.2K Q2 '18: 574.5K Q3 '18: 686.8K Q4 '18: 625.5K Q1 '19: 1.1M Q2 '19: 1.9M Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -10.4M Q4 '21: -12.8M Q1 '22: -17.1M Q2 '22: -18.8M Q3 '22: -29.5M Q4 '22: -31.8M Q1 '23: -31.1M Q2 '23: -30.4M Q3 '23: -18.4M Q4 '23: -12.9M Q1 '24: -9.2M Q2 '24: -6.7M Q3 '24: -5.2M Q4 '24: -5.7M Q1 '25: -5.7M Q2 '25: -5.2M Q3 '25: -5.1M Q4 '25: -12.6M Q1 '26: -13.2M Q2 '26: -14.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -10.4M Q4 '21: -12.8M Q1 '22: -17M Q2 '22: -18.7M Q3 '22: -29.3M Q4 '22: -31.6M Q1 '23: -30.8M Q2 '23: -30M Q3 '23: -18M Q4 '23: -12.5M Q1 '24: -8.9M Q2 '24: -6.5M Q3 '24: -5M Q4 '24: -5.6M Q1 '25: -5.6M Q2 '25: -5.1M Q3 '25: -5M Q4 '25: -12.5M Q1 '26: -13M Q2 '26: -14.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 200K 400K 600K Q4 '17: 506.5K Q1 '18: 511.4K Q2 '18: 546K Q3 '18: 489.2K Q4 '18: 430.8K Q1 '19: 394.1K Q2 '19: 250.3K Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19

Operating Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '21: -8.9M Q4 '21: -10.2M Q1 '22: -11M Q2 '22: -11.4M Q3 '22: -15.6M Q4 '22: -17.6M Q1 '23: -17.2M Q2 '23: -18M Q3 '23: -16M Q4 '23: -12.8M Q1 '24: -11M Q2 '24: -7.7M Q3 '24: -5.3M Q4 '24: -4.5M Q1 '25: -4.4M Q2 '25: -4.1M Q3 '25: -4.4M Q4 '25: -4.8M Q1 '26: -6.5M Q2 '26: -8.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q4 '15: -21M Q1 '16: -26.1M Q2 '16: -31.1M Q3 '16: -31.7M Q4 '16: -32.6M Q1 '17: -31.6M Q2 '17: -27.8M Q3 '17: -28.4M Q4 '17: -27.8M Q1 '18: -29M Q2 '18: -31.5M Q3 '18: -2M Q4 '18: 4.2M Q4 '15 Q2 '16 Q4 '16 Q2 '17 Q4 '17 Q2 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 14M Q3 '20: 18M Q1 '21: 30.6M Q2 '21: 44.8M Q3 '21: 1.8M Q1 '22: 1.9M Q2 '22: 2.1M Q3 '22: 2.2M Q1 '23: 2.4M Q2 '23: 338.6K Q3 '23: 469.3K Q1 '24: 524.3K Q2 '24: 600.4K Q3 '24: 85.5K Q1 '25: 7.1K Q2 '25: 11.8K Q3 '25: 481.6K Q1 '26: 532K Q2 '26: 532K Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-140.00 -70.00 0.00 70.00 140.00 210.00 Q3 '20: -0.89 Q4 '20: -0.55 Q1 '21: -0.39 Q2 '21: -0.33 Q3 '21: -2.32 Q4 '21: -4.53 Q1 '22: -7.77 Q2 '22: -9.90 Q3 '22: -14.22 Q4 '22: -14.66 Q1 '23: -13.59 Q2 '23: -22.84 Q3 '23: -21.64 Q4 '23: -18.92 Q1 '24: -19.96 Q2 '24: -10.88 Q3 '24: -17.05 Q4 '25: -129.10 Q1 '26: 106.79 Q2 '26: 183.54 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.